Figure 5

Figure 5

PUFA analogues do not shorten the zebrafish AP in LQT2 drug-induced conditions. (A) Representative zebrafish AP traces before (black) and after sequentially applying E4031 (10 µM, red) and E4031/DHA-Gly (10 µM/20 µM, dark green). (B) ΔAPD80 (%) measured at different recording times (10, 20, and 30 min after application of the combination drug/PUFA analogue). The E4031 recording, measured at 30 min, was used as the control condition. (C) ΔAPD (%) produced by the combination of drug/PUFA analogue measured for the APD25, APD50, APD80, and APD90. (D) Effect of the combination of drug/PUFA analogue on phase 3 of the AP. APD80–APD25 in E4031 (control conditions) and after E4031/DHA-Gly application. (E–H) The same as (A–D) but for the combination E4031/LIN-Gly (10 µM/20 µM) (mean ± SEM; ^#p <0.05 vs. E4031 condition). Each symbol in panels D and H represent data from a different experiment.